Inhibition of Murine Systemic Leishmaniasis by Acetyl Salicylic Acid via Nitric Oxide Immunomodulation
,
Abstract
Background: The purpose of this study was to evaluate antileishmanial effects of ASA via NO pathway in Leishmania major infected Balb/c mice. Moreover, toxicity and pathological consequences of ASA administration were investigated.
Methods: Balb/c mice were infected with L. major and ASA was inoculated orally after lesion appearance for its ability to modulate NO and to modify Leishmania infection in host, in order to evaluate the effects of NO production on size and lesion macroscopy, delay of lesion formation and proliferation of amastigotes inside macrophages. Liver, spleen, and lymph nodes were also studied as target organs to detect amastigotes. In addition, plasma was investigated for NO induction using Griess microassay.
Results: ASA increased NO production in plasma of both naïve and Leishmania test groups at the ultimate of the experimental period. A decline was observed in proliferation of amastigotes inside macrophages of test group when compared with control one. ASA reduced lesion size, inhibited Leishmania visceralisation in spleen, lymph node, and decreased hepato/splenomegaly in ASA treated animals.
Conclusions: Some antileishmanial effects of ASA by NO-modulation were indicated during systemic leishmaniasis in mice. Despite slight effects on lesion size, ASA decreased parasite visceralization in target organs and declined their proliferation inside macrophages. Therefore, ASA may be indicated to inhibit systemic leishmaniasis via NO pathway in mice model.
Erel O, Kocyigit A, Bulut V, Salih Gurel M. Reactive nitrogen and oxygen intermdiatesin patients with cutaneuse lieshmaniasis. Mem Inst Osw Cruz. 1999; 94:179-183.
Li J, Hunter CA, Farrel JP. Anti-TGF-β treatement promotes rapid hesling of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol. 1999; 162: 974-979.
Oliveira SHP, Fonseca SG, Romao PRT, Ferreira SH, Cunha FQ. Nitric ocide mediates the microbicidal activity of eonsinophils. Mem Inst Osw Cruz. 1997; 92:233-235.
Megson L. Nitric oxide donor drugs. Drug Future. 2000; 25:701-715.
Nahrevanian H, Amini M. Nitric oxide functions; an emphasis on its diversity in infectious diseases. Irn J BasicMed Sci. 2009; 11(4):197-204.
Vainio H, Morgan G. Aspirin for the second hundred years: new uses for an old drug. Pharmacol Toxicol. 1997; 81(4):151-152.
Morris T, Stables M, Gilroy DW. New perspectives on aspirin and the endogenous control of acute inflammatory resolution. Sci World J. 2006; 6:1045–1068.
Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: The effect of positional isomerism. J Pharmacol Exp Therap. 2004; 312(3):989-997.
Hulsman N,Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, et al. Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem. 2007; 50(10):2424-2431.
Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, et al. Heme oxygenase- 1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003; 308(4):956-960.
Gilroy DW. New insights into the antiinflammatory actions of aspirin- induction of nitric oxide through the generation of epilipoxins. Mem Inst Osw Cruz. 2005; 100(1):49-54.
Kavoosi G, Ardestani S K, Kariminia A, Tavakoli Z. Production of nitric oxide by murine macrophages induced by lip ophosphoglycan of Leishmania major. Kor J Parasitol. 2006; 44:35-41.
El-on J, Witztum A, Schnur LF. Production ofGuinea pigs against cutaneus leishmaniasis by combined infection and chemotherapy. Infect Immun. 1986; 51:704-706.
Nahrevanian H, Najafzadeh M, HajihosseiniR, NazemH, Farahmand M,Zamani Z. The therapeutic antileishmanial effects of Trinitroglycerin in BALB/C mice infected with Leishmania major via nitric oxide pathway. Kor J Parasitol. 2009; 47(2):109-115.
Nahrevanian H, Farahmand M, Aghighi Z, Assmar M, Amirkhani A. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER; An Iranian strain of cutaneous leishmaniasis. Exp Parasitol. 2007; 116(3):233-240.
Nahrevanian H, Dascombe MJ. Nitric oxide and reactive nitrogen intermediates during lethal and non-lethal strains of murine malaria. Parasite Immunol. 2001; 23:491-501.
Nahrevanian H. Involvement of nitric oxide and its up/down stream molecules in the immunity of parasitic infections. Braz J InfectDis. 2009; 13(6):440-448.
Nahrevanian H, Hajihosseini R, Arjmand M, Farahmand M, Ghasemi F. Evaluation of anti-leishmanial activity by induction of nitric oxide and inhibition of prostaglandin in Balb/c mice infected with Leishmania major. SE Asian J Trop Med Pub Health. 2009; 40(6):1188-1198.
Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun. 2000; 68:1760-1764.
Arevalo I, Ward B, Matlashewski G. Detection of iNOS gene expression in cutaneous leishmaniasis biopsy tissue. Mol Biochem Parasitol. 2002; 121:145-147.
Qadoumi M, Becker I, Donhauser N, Rollinghoff M, Bogdan C. Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis. Infect Immun. 2002; 70:4638-2642.
Fritzsche C, Schleicher U, Bogdan C.Endothelial nitric oxide synthase limits the inflammatory response in mouse cutaneous leishmaniasis. Immunobiol. 2010; 215(9-10):826-832.
Kumar R, Bumb RA, Salotra P. Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors. Immunol. 2010; 130(2):193-201.
De Trez C, Magez S, Akira S, Ryffel B, Carlier Y, Muraille E. iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog. 2009; 5(6):e1000494.
de Souza GF, Yokoyama-Yasunaka JK, Seabra AB, Miguel DC, de Oliveira MG, Uliana, SR. Leishmanicidal activity of primary Snitrosothiols against Leishmania major and Leishmania amazonensis: Implications for the treatment of cutaneous leishmaniasis, Nitric Oxide. 2006; 15(3):209-216.
Hennekens CH, Schneider WR, Pokov A, Hetzel S,DemetsD, SerebruanyV, Schröder H. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. JCardiovasc PharmacolTher. 2010; 5(4):344-348.
Jowkar F, Dehghani F, Jamshidzadeh A. Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis? J Dermatolog Treat. 2010. [Epub ahead of print]
Wilkins-Rodríguez AA, Escalona-Montaño AR, Aguirre-García M, Becker I, Gutiérrez- Kobeh L. Regulation of the expression of nitric oxide synthase by Leishmania mexicana amastigotes in murine dendritic cells. Exp Parasitol. 2010; 126(3):426-434.
| Files | ||
| Issue | Vol 7 No 2 (2012) | |
| Section | Articles | |
| Keywords | ||
| ASA Balb/c Leishmania major Immunotherapy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
